ASH News TV 2018: Coverage of 60th ASH
congress program
Discover the establishment of a robust and reproducible in vitro screening
platform to support preclinical macrophage therapy and anti-CD47 agent
drug development. Learn how disrupting the CD47-SIRPa anti-phagocytic
axis is a novel immunotherapy approach against cancer.